Catheter Precision
VTAK
9 hedge funds and large institutions have $1.82M invested in Catheter Precision in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.
80% more funds holding
Funds holding: 5 → 9 (+4)
0% less ownership
Funds ownership: 0% → 0% (-0%)
17% less capital invested
Capital invested by funds: $2.19M → $1.82M (-$364K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$770K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$193K |
| 3 |
Two Sigma Advisers
New York
|
+$193K |
| 4 |
Two Sigma Investments
New York
|
+$193K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$38K |
| 2 |
BlackRock
New York
|
-$22K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$4K |
| 4 |
EWM
EPG Wealth Management
Atlanta,
Georgia
|
-$1K |
VTAK Hedge Fund Activity: Q2 2020 in Review
9 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Catheter Precision (VTAK) for Q2 2020, worth a combined $1.82M — down 17% from $2.19M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VTAK positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $770K. The largest seller was Putnam Investments, cutting an estimated $38K.
- 9 institutional investors held Catheter Precision (VTAK) as of Q2 2020, up from 5 in Q1 2020.
- Funds reported $1.82M of Catheter Precision stock for Q2 2020, down 17% quarter-over-quarter.
- 4 funds opened new Catheter Precision positions in Q2 2020 and 0 closed out, a net change of +4 holders.
- The largest Catheter Precision buyer in Q2 2020 was Renaissance Technologies, an estimated $770K added.
- The largest Catheter Precision seller in Q2 2020 was Putnam Investments, an estimated $38K sold.
Based on aggregated 13F filings for Q2 2020.